Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omeros reports record earnings, navigates FDA challenges for growth

Omeros showcased strong financial performance, a robust pipeline, and strategic partnerships in Q4 2022.
While challenges like FDA concerns and tight timelines exist, the company is well-positioned to capitalize on growth opportunities.
With a focus on advancing key programs and maintaining financial stability, Omeros aims to deliver value to shareholders and patients.

Omeros reports Q1 loss, progresses in key programs amid challenges

Omeros' Q1 2023 performance reflected a shift from net income to a significant loss, driven by increased expenses and reduced income, while maintaining a strong cash position and positive sales figures for OMIDRIA.
The company showcased strengths in diversified revenue streams, progress in key clinical programs, and inclusion in the Russell 3000 Index, signaling growth potential and market recognition.
Challenges in regulatory processes, market competition, and resource allocation were evident, requiring strategic navigation and operational efficiency to overcome hurdles and drive future success.
Amidst challenges, Omeros identified opportunities in expanding royalties, advancing clinical programs, exploring new indications, and leveraging immuno-oncology advancements to drive future growth and innovation.

Omeros reports Q2 loss, eyes FDA decisions and revenue growth

Omeros faces challenges with debt maturity and regulatory approvals but benefits from strong revenue streams
The company's pipeline shows promise in addressing various diseases, with a focus on high unmet medical needs
Opportunities lie in expanding revenue through OMIDRIA and advancing key drug candidates towards approval

Omeros reports Q3 losses, highlights pipeline strength and regulatory progress

Omeros demonstrated a mixed financial performance in Q3 2023 but showcased strength in its pipeline and strategic alignment with regulatory authorities.
Challenges persist in financial metrics and regulatory timelines, necessitating a balance between innovation and operational efficiency.
The company's opportunities in immuno-oncology and stable revenue streams position Omeros for future growth and impact in the biopharmaceutical landscape.

Omeros extends cash runway, advances key pipeline candidates for growth

Omeros demonstrated improved financial performance, securing additional funding and advancing key pipeline candidates, positioning the company for future growth.
While facing challenges in regulatory processes and anticipated losses, Omeros' strategic priorities and innovative pipeline offer opportunities for long-term success.
Management's focus on financial stability, operational efficiency, and product differentiation underscores Omeros' commitment to delivering value to shareholders and patients.

Omeros reports increased net loss but optimistic about pipeline progress

Omeros faced a significant increase in net loss in Q1 2024 but maintains a strong financial position with $230.3 million in cash and investments.
The company's development programs, especially OMS906, show promise with positive trial results and potential milestone payments tied to OMIDRIA sales.
While challenges like regulatory approvals and competition exist, Omeros is optimistic about its pipeline and aims for Phase III trials and regulatory successes.
Overall, Omeros is strategically positioned to leverage opportunities for growth and diversification in the biopharmaceutical market.

Omeros reports improved Q3 performance with promising drug developments

Omeros' Q3 2024 performance showed improvements in net loss and strategic financial decisions.
The company's strengths lie in potential revenue streams from OMIDRIA sales and positive trial data.
Challenges include regulatory hurdles and managing costs amidst multiple development programs.
Opportunities exist in sales growth, milestone payments, and advancing key drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omeros (OMER) delivered earnings and revenue surprises of 1.96% and -5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Omeros (OMER) Reports Q1 Loss, Misses Revenue Estimates

Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 7.55% over the past year to ($0.57), which were in line with the estimate of ($0.57).

Omeros: Q1 Earnings Insights

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31,

Omeros Corporation Reports First Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone, ple

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). The absence of a specific HSCT-TMA diagnosis code has led to underreporting of diagnoses and inaccurate coding, which has complicated reporting of the incidence and outcomes of the dis

Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration

FDA action approving narsoplimab in treatment of HSCT-TMA in Omeros' upcoming PDUFA date has the potential to vault Omeros into multibagger territory overnight. Omeros' narsoplimab in treatment of severely ill COVID-19 patients presents an interesting opportunity.

Omeros: The Prize Is Nigh

SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoi

Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

Omeros Corp (OMER) CEO Greg Demopulos on Q4 2020 Results - Earnings Call Transcript

Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates

Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the estimate of ($0.64).

Recap: Omeros Q4 Earnings

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and

Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference c

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021

Omeros' Biologics License Application (BLA) for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021. This BLA is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a rare, unmet, life-threatening disease.

Omeros: Multibagger On The Horizon

Omeros has doubled since my last (10/20) bullish article. The company is still vastly undervalued with its current market cap of ~$1.3 billion.

Omeros: On A Tear, More To Come

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the company's mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. A Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated

Omeros Hires Nadia Dac as Chief Commercial Officer

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The BLA has been granted Priority Review with an FDA action date of July 17, 2021 under the Prescription Drug User Fee Act (PDUFA). FDA also indicated in its filing letter that the

Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference this year. The presentation is scheduled for Wednesday, January 13, 2021 at 10:50 a.m. EST. The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company

Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference

Omeros: A Ripening Fruit Ready To Pick

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros' cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient prospective payment system (OPPS) and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment

CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRIA® in Ambulatory Surgery Centers

Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Omeros (OMER) in Focus: Stock Moves 8.5% Higher

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough ther

Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended

Omeros Corporation Reports Third Quarter 2020 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via pho

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners entitled COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly. The presentation, which is part of a session on immune modulators to ameliorate COVID-19, is being made by Gregory A. Demopulos, M.D

News for Omeros Stock (OMER)